US FDA Panel Nod For Teplizumab To Delay Type 1 Diabetes Comes On Strength Of Single Study

 
• By Sue Sutter
  
Boy with insulin
The panel majority found sufficient evidence that teplizumab delays the onset of type 1 diabetes. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers